Mersana Therapeutics buy Truist Financial Co.
Start price
29.02.24
/
50%
€5.00
Target price
28.02.25
€8.30
Performance (%)
-62.40%
Price
29.07.24
€1.88
Summary
This prediction is currently active. The BUY prediction by Truist_Financial_Co_ for Mersana Therapeutics is performing very badly with a performance of -62.40%. This prediction currently runs until 28.02.25. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Mersana Therapeutics | -7.069% | -7.069% |
iShares Core DAX® | -0.621% | 1.080% |
iShares Nasdaq 100 | -4.503% | -5.432% |
iShares Nikkei 225® | -2.562% | -1.617% |
iShares S&P 500 | -1.706% | -1.223% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Mersana Therapeutics diskutieren
Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat